HCWB
vs
S&P 500
HCWB
S&P 500
Over the past 12 months, HCWB has underperformed S&P 500, delivering a return of -90% compared to the S&P 500's +14% growth.
Stocks Performance
HCWB vs S&P 500
Performance Gap
HCWB vs S&P 500
Performance By Year
HCWB vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
HCW Biologics Inc
Glance View
HCW Biologics Inc. is a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases. The company is headquartered in Miramar, Florida and currently employs 44 full-time employees. The company went IPO on 2021-07-20. The company focuses on discovering and developing immunotherapies designed to improve health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, and autoimmune diseases. The firm uses its TOBI (Tissue factOr-Based fusIon) discovery platform to generate designer, multi-functional fusion molecules with immunotherapeutic properties for the treatment of inflammaging. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is an injectable, fusion protein complex designed to drive bifunctional antitumor activity by activating desired immune responses to attack cancer cells while simultaneously blocking unwanted immunosuppressive activities. The company is developing HCW9302 as an IL-2-based immunotherapeutic to stimulate regulatory T (Treg) cells to suppress the activity of inflammasome-bearing cells and inflammatory factors.
